The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinomaHye Ryun Kim, Byoung Chul Cho, J. K. Park et al.|Annals of Oncology|2013Cited by 125
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81